However, a case series performed on PTCL tumors had found substantial CTLA-4 mutations in various subtypes of PTCL, notably in that of AITL and PTCL-NOS, suggesting possible room for therapeutics against the CTLA-4 surface marker in future studies (129). The gene discussed is CTLA4; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.